Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma

Dr. Gary S. Jacob, CEO of OKYO Pharma OKYO, was recently a guest on Benzinga’s All Access.

OKYO Pharma is a biotechnology company focused on the treatment of ocular diseases. OKYO is currently developing OK-101 to treat dry eye disease, which is a currently underserved and untreated condition affecting millions of people in the U.S. According to the company, the addressable market exceeds $5 billion.

OK-101 has just had its First Patient First Visit, marking the beginning of its phase 2 trials. The company is very excited about this event and says it expects top line data by the end of the year.

Watch the full interview here:

Featured photo by v2osk on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.